PuYin Wealth Management YueFengLi Increase Profit No. 317 will be issued starting April 8. The performance benchmark for Share A is 2.75% - 3.15%.

LightningPacketLoss · 2026-04-09T02:00:21+00:00

PuYin Wealth Management recently announced the YueFengLi ZengYing 317 financial product, with a subscription period from April 8 to April 14, 2026. The minimum investment amount is 1 yuan, and the maximum scale is 5 billion yuan. This product is a fixed-income type, with a risk level of R2, a term of 799 days, and Class A has an annualized benchmark return between 2.75% and 3.15%, while Class B ranges from 2.80% to 3.20%. Investment should be made cautiously.

LightningPacketLoss

2026-04-09 02:00:21

Abstract generation in progress

On April 8, according to Puyin Wealth Management’s disclosure, the subscription period for its Yuefeng Lixin Ying No. 317 wealth management product runs from April 8, 2026 to April 14, 2026. The minimum subscription amount is 1 yuan. The product’s maximum issuance size is 5 billion yuan, and the minimum is 10M yuan. The product type is fixed-income, with a product risk level of R2 (low risk). The product term is 799 days. The performance comparison benchmark for Class A shares (annualized) is 2.75%–3.15%, and for Class B shares (annualized) it is 2.80%–3.20%.

Note: The performance comparison benchmark is not a forecast of the expected return rate; it does not indicate the product’s future performance and actual returns, and does not constitute a commitment regarding the product’s returns.

The information above about these wealth management products is for reference only; the specific details shall be subject to sales documents such as the “Product Prospectus.” This article does not constitute any investment advice. Investors act at their own risk and bear the risks accordingly.

(Puyin Wealth Management)

(Editor: Qian Xiaorui)

Keywords:

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.